- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03010696
The Correlation Between Gut Microbiome/Metabolite and End Stage Renal Disease (ESRD)
October 21, 2020 updated by: Fazheng Ren, China Agricultural University
The purpose of this study is to investigate the differences of gut Microbiome/Metabolite between ESRD patients and healthy subjects.
Two hundred and twenty three hemodialysis patients and 70 healthy subjects are recruited, and a cross-sectional study is performed.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
293
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100144
- Peking University Shougang Hospital
-
Beijing, China, 100029
- Beijing Anzhen Hospital
-
Beijing, China, 100039
- General Hospital of Chinese Armed Police Forces
-
Beijing, China, 100049
- Peking University Aerospace Centre Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Two hundred and twenty three ESRD patients with hemodialysis are recruited from Department of Nephrology of 4 hospitals.
Seventy healthy subjects are also recruited to compare the microbiome/metabolite differences between two groups.
Description
For Healthy Subjects
Inclusion Criteria:
- Age over 18 years old
- Liver and kidney function is normal
- 18.5≤BMI≤29.9
- Agree to sign the informed consent form
Exclusion Criteria:
- Diagnosed as Metabolic syndrome
- Diagnosed as Cirrhosis
- Diagnosed as kidney disease
- Taking fermented food (live lactic acid bacteria drinks, cheese, yogurt, probiotic products, etc.) within 14 days before the study
- Taking antibiotics or antifungal drugs within 30 days before the study
For ESRD patients
Inclusion criteria:
- Age over 18 years old
- Patients who diagnosed as ESRD with hemodialysis
- Fixed hemodialysis cycle (average 3 times a week)
- Agree to sign the informed consent form
Exclusion criteria:
- Taking antibiotics or antifungal drugs within 30 days before the study
- Taking fermented food (live lactic acid bacteria drinks, cheese, yogurt, probiotic products, etc.) within 14 days before the study
- Reasercher are not sure whether the subjects are willing or able to complete the study
- Subject participated in other research projects within two months before the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Healthy subjects
Normal kidney function
|
|
|
ESRD patients
Diagnosed as ESRD with hemodialysis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Microbiota-derived uremic toxin
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fecal Microbiome
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
|
Fecal metabolites
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
|
Blood metabolites
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
|
Complete blood count
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
|
Blood biochemistry test
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Fazheng Ren, PhD, China Agricultural Universtiy
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Vaziri ND, Wong J, Pahl M, Piceno YM, Yuan J, DeSantis TZ, Ni Z, Nguyen TH, Andersen GL. Chronic kidney disease alters intestinal microbial flora. Kidney Int. 2013 Feb;83(2):308-15. doi: 10.1038/ki.2012.345. Epub 2012 Sep 19.
- Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, Meyer TW. Colonic contribution to uremic solutes. J Am Soc Nephrol. 2011 Sep;22(9):1769-76. doi: 10.1681/ASN.2010121220. Epub 2011 Jul 22.
- Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014 Apr;25(4):657-70. doi: 10.1681/ASN.2013080905. Epub 2013 Nov 14.
- Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 2013 Jun;83(6):1010-6. doi: 10.1038/ki.2012.440. Epub 2013 Jan 16.
- Poesen R, Windey K, Neven E, Kuypers D, De Preter V, Augustijns P, D'Haese P, Evenepoel P, Verbeke K, Meijers B. The Influence of CKD on Colonic Microbial Metabolism. J Am Soc Nephrol. 2016 May;27(5):1389-99. doi: 10.1681/ASN.2015030279. Epub 2015 Sep 23.
- Koppe L, Mafra D, Fouque D. Probiotics and chronic kidney disease. Kidney Int. 2015 Nov;88(5):958-66. doi: 10.1038/ki.2015.255. Epub 2015 Sep 16.
- Poesen R, Claes K, Evenepoel P, de Loor H, Augustijns P, Kuypers D, Meijers B. Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. J Am Soc Nephrol. 2016 Nov;27(11):3479-3487. doi: 10.1681/ASN.2015121302. Epub 2016 May 26.
- Meyer TW, Hostetter TH. Uremia. N Engl J Med. 2007 Sep 27;357(13):1316-25. doi: 10.1056/NEJMra071313. No abstract available.
- Wang X, Yang S, Li S, Zhao L, Hao Y, Qin J, Zhang L, Zhang C, Bian W, Zuo L, Gao X, Zhu B, Lei XG, Gu Z, Cui W, Xu X, Li Z, Zhu B, Li Y, Chen S, Guo H, Zhang H, Sun J, Zhang M, Hui Y, Zhang X, Liu X, Sun B, Wang L, Qiu Q, Zhang Y, Li X, Liu W, Xue R, Wu H, Shao D, Li J, Zhou Y, Li S, Yang R, Pedersen OB, Yu Z, Ehrlich SD, Ren F. Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents. Gut. 2020 Dec;69(12):2131-2142. doi: 10.1136/gutjnl-2019-319766. Epub 2020 Apr 2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2015
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
December 28, 2016
First Submitted That Met QC Criteria
January 3, 2017
First Posted (Estimate)
January 5, 2017
Study Record Updates
Last Update Posted (Actual)
October 22, 2020
Last Update Submitted That Met QC Criteria
October 21, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAUPCKD-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Failure, Chronic
-
Centre Hospitalier Universitaire DijonTerminatedEnd-stage Chronic Kidney FailureFrance
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Angiodynamics, Inc.TerminatedChronic Kidney Disease | Acute Kidney Injury | Acute Renal Failure | Renal Failure Chronic Contrast InducedUnited States
-
Hopital Jean MinjozUnknownCardiac Surgical Procedures | Preoperative KIDNEY FAILURE, CHRONIC | Postoperative KIDNEY FAILURE, ACUTEFrance
-
Pharmagest InteractiveCompletedChronic Kidney DiseasesFrance
-
Ozge AKBABAAtaturk UniversityCompletedChronic Kidney FailureTurkey
-
Chinese PLA General HospitalCompletedKidney Failure,ChronicChina
-
Fatma Alzahraa Mohamed Ibrahim Hassan HaggagUnknown
-
Federal University of Health Science of Porto AlegreCompleted
-
Bristol-Myers SquibbCompletedKidney Transplantation | Chronic Kidney FailureUnited States, Argentina, Australia, Germany, Italy, South Africa, Spain, Brazil, Mexico, Belgium, France, Hungary, Switzerland, India, Canada, Austria, Czech Republic, Poland, Israel, Sweden, Turkey
Clinical Trials on No interventions, questionnaire, collect specimen
-
Abant Izzet Baysal UniversityActive, not recruitingPeriodontal DiseaseTurkey (Türkiye)
-
Centers for Disease Control and PreventionNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertensionUnited States
-
National Taiwan University HospitalNot yet recruitingThe Cardiac Function
-
Johns Hopkins UniversityWithdrawnInterstitial Cystitis | Painful Bladder Syndrome | Prostatitis | Chronic Prostatitis | Bladder Pain SyndromeUnited States
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Chinese University of Hong KongRecruiting
-
Thomas Jefferson UniversityRecruiting
-
Royal Brompton & Harefield NHS Foundation TrustRecruitingIdiopathic Pulmonary Fibrosis (IPF) | Progressive Pulmonary FibrosisUnited Kingdom
-
University of IoanninaEnrolling by invitationCarpal Tunnel Syndrome (CTS)Greece
-
Marmara UniversityCompleted